Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BOGER JOSHUA S						2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								5. Relationship of Reporting (Check all applicable) X Director Officer (give title			g Perso	Person(s) to Issuer 10% Owner Other (specify	
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED					3. Date of Earliest Transaction (Month/Day/Year) 09/23/2015									below)	(give title		below)	респу	
50 NORTHERN AVENUE					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) BOSTON	•												X		led by One led by More		•		
(City)	City) (State) (Zip)																		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/					Execu	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			Benefic Owned		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			(Instr. 4)
Common Stock 09/				09/23/2	09/23/2015				M		10,400	A	\$35	5.64	355	5,684		D	
Common Stock 09/2				09/23/2	09/23/2015				S ⁽¹⁾		1,000	D	\$109.	09(2)(3)	354	4,684		D	
Common Stock 0				09/23/2	09/23/2015				S ⁽¹⁾		1,200	D	\$110 .	23(2)(4)	353	3,484		D	
Common Stock				09/23/2	09/23/2015				S ⁽¹⁾		4,288	D	\$111.	111.35(2)(5)		9,196		D	
Common Stock 09/23/				09/23/2	.015				S ⁽¹⁾		1,310 D \$112.45 ⁽²⁾⁽⁶⁾ 34		347	7,886		D			
Common Stock 0				09/23/2	09/23/2015				S ⁽¹⁾		800	D	\$113.	\$113.37 ⁽²⁾⁽⁷⁾		47,086		D	
Common Stock 09/23/				2015				S ⁽¹⁾		1,300	D	\$114.58(2)(8)		345,786			D		
Common Stock 09/23/201				2015	.5			S ⁽¹⁾		502	D	\$115.34 ⁽²⁾⁽⁹⁾		345,284			D		
Common Stock														13	,286		I	401(k)	
Common Stock													122,700			I	Common Stock held in trust		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
Security or Exercise (Month/Day/Year) if any			tion Date, Tra		action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Dat Expira (Mont	ation E		7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		D	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amo or Num of Shar	ber					
Stock Option (right to buy)	\$35.64	09/23/2015			M			10,400	(1	0)	02/01/2016	Commo Stock		400	\$0.00	188,000		D	

Explanation of Responses:

- 1. Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- 2. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- $3. \ Open \ market \ sales \ reported \ on \ this \ line \ occurred \ at \ a \ weighted \ average \ price \ of \$109.09 \ (range \$108.58 \ to \$109.50).$
- 4. Open market sales reported on this line occurred at a weighted average price of \$110.23 (range \$109.75 to \$110.59).
- $5. \ Open \ market \ sales \ reported \ on \ this \ line \ occurred \ at \ a \ weighted \ average \ price \ of \$111.35 \ (range \$110.88 \ to \$111.86).$
- 6. Open market sales reported on this line occurred at a weighted average price of \$112.45 (range \$112.00 to \$112.86).
- 7. Open market sales reported on this line occurred at a weighted average price of \$113.37 (range \$113.00 to \$113.82). 8. Open market sales reported on this line occurred at a weighted average price of \$114.58 (range \$114.20 to \$114.95).
- 9. Open market sales reported on this line occurred at a weighted average price of \$115.34 (range \$115.25 to \$115.40).

10. Fully vested. Remarks:

Omar White, Attorney-In-Fact 09/24/2015

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.